INSIGHT

Rare Disease Commercialization

Why small patient populations, complex care pathways, specialized stakeholder networks, and access dynamics require a different approach to commercialization.

By Mónica González –

Rare disease commercialization is sometimes approached as a more specialized version of conventional pharmaceutical commercialization. In my experience, that understates the difference.

When patient populations are small, diagnosis can take years, clinical expertise is concentrated, treatment pathways are highly specialized, evidence may remain limited at launch, and access conditions vary significantly between markets, almost every commercialization decision becomes interconnected.

The challenge is not simply reaching a smaller audience. It is understanding and enabling a healthcare environment in which finding, diagnosing, referring, treating, supporting, and securing access for individual patients can all influence whether an innovation reaches the people who may benefit from it.

The patient journey often begins before treatment choice

In many therapeutic areas, commercialization focuses heavily on what happens once a patient reaches a treatment decision. In rare disease, one of the most important challenges may occur much earlier.

Patients can move through multiple healthcare professionals and specialties before receiving an accurate diagnosis. Awareness may be low, symptoms heterogeneous, diagnostic pathways fragmented, and appropriate testing inconsistently available. Even after diagnosis, referral to a center with relevant expertise may create another barrier.

This means organizations need to understand the full patient journey, not merely the point at which a treatment becomes available. Medical education, disease awareness, diagnostic pathways, referral networks, testing, specialist capacity, and treatment infrastructure can all influence real-world adoption.

In rare disease, commercialization cannot begin with the product. It has to begin with understanding how patients reach diagnosis, specialist care, access, and treatment.

Small populations increase the importance of individual pathways

A small patient population does not necessarily create a simpler commercialization model. It can make every part of that model more consequential.

When eligible patients are relatively few, losing individuals through delayed diagnosis, unclear referral pathways, access barriers, or inadequate treatment infrastructure can materially affect both patient outcomes and commercialization performance.

Aggregate market assumptions can also conceal important differences. Patients with the same disease may encounter very different pathways depending on geography, healthcare infrastructure, specialist availability, reimbursement conditions, or the maturity of local disease networks.

This requires greater precision in understanding where patients are, how they move through the healthcare system, and where the pathway prevents them from reaching appropriate care.

Stakeholder relationships are unusually interconnected

Rare disease communities are often relatively concentrated. Specialist clinicians, centers of expertise, researchers, patient organizations, caregivers, payers, and other stakeholders may interact repeatedly within the same disease environment.

Their perspectives are different, but they are not independent.

Scientific credibility matters deeply. Patient organizations may have substantial knowledge of unmet needs and real-world experience. Caregivers can play a significant role in treatment decisions and ongoing care. Payers may need to evaluate significant uncertainty around evidence, population size, outcomes, and long-term value.

Commercialization therefore requires more than coordinated stakeholder engagement. It requires an organization to understand how these perspectives interact and to engage each stakeholder appropriately without reducing the disease community to a commercial audience.

Trust is particularly difficult to build and remarkably easy to damage in a small, connected community.

Evidence and access shape commercialization from the beginning

In rare disease, evidence generation and market access cannot be treated as activities that become important only as launch approaches.

Small populations can limit traditional evidence generation. Clinical endpoints may be complex. Natural history may be incompletely understood. Payers may face significant uncertainty while evaluating therapies with high individual treatment costs. Requirements can vary considerably between markets.

These realities affect decisions well beyond the access function. They can influence evidence strategy, medical engagement, launch sequencing, market prioritization, patient identification, stakeholder expectations, and the capabilities required at affiliate level.

Commercialization planning therefore needs to connect scientific, medical, access, and market considerations early enough for those dependencies to shape the strategy rather than emerge as late execution constraints.

Global strategy needs unusually strong local understanding

Rare diseases are global, but the ability to diagnose, refer, fund, and treat patients is highly local.

One market may have established centers of expertise and clear referral pathways, while another has fragmented specialist networks. Diagnostic testing may be routinely available in one country and difficult to access in another. Patient organizations vary in maturity and role. Reimbursement mechanisms, treatment infrastructure, and stakeholder expectations can differ substantially.

A single global commercialization model cannot simply be replicated across those environments.

The organization needs a coherent global strategy while allowing markets to build execution around the realities of their individual disease environment. This makes affiliate readiness particularly important: local teams need not only product knowledge, but a deep understanding of the patient pathway, stakeholder network, access environment, and operational barriers affecting treatment.

Cross-functional execution is inseparable from the commercialization model

The interdependencies inherent in rare disease make functional separation particularly difficult.

Medical insights can reshape patient identification. Access developments can affect market sequencing. Regulatory outcomes can alter evidence requirements. Patient engagement can reveal barriers that change operational priorities. Commercial decisions can have implications for stakeholder trust and scientific credibility.

The objective is not to have every function involved in every decision. It is to identify where decisions genuinely cross functional boundaries and ensure that ownership, information, and accountability remain clear.

This is where experienced leadership becomes particularly valuable. Rare disease environments frequently involve decisions for which there is limited precedent, incomplete information, or legitimate competing perspectives. Those situations require judgment as much as process.

AI can improve understanding without replacing human context

AI creates meaningful opportunities in rare disease commercialization. It can support research and evidence synthesis, identify patterns across fragmented information, improve knowledge retrieval, help teams understand complex stakeholder environments, accelerate analysis, and reduce administrative work across commercialization activities.

These capabilities are particularly relevant where information is dispersed and populations are small.

But rare disease also illustrates the limits of treating greater analytical capability as equivalent to better commercialization. Data may be incomplete. Small populations make context important. Patient and caregiver experiences cannot be understood purely as data points. Scientific and stakeholder relationships require credibility, empathy, and judgment.

AI can strengthen the organization’s ability to understand and execute. It should not replace the human interpretation and relationships on which rare disease commercialization depends.

Human-Led. AI-Enabled.

Rare disease commercialization is ultimately about enabling patient access

Commercial success remains essential. Without sustainable commercialization, innovation cannot continue. But in rare disease, the route to commercial success is unusually dependent on whether the broader healthcare environment can identify the right patients and enable them to reach appropriate treatment.

That requires organizations to understand disease pathways, build scientific credibility, engage specialized stakeholder communities appropriately, anticipate evidence and access requirements, prepare markets for execution, and coordinate decisions across functions.

The strongest rare disease commercialization models therefore connect business objectives with the realities of how patients actually move through healthcare systems.

When those realities shape commercialization from the beginning, organizations are better positioned to create sustainable adoption while helping appropriate patients reach innovations that may materially change their lives.